0001428336-24-000022.txt : 20240514 0001428336-24-000022.hdr.sgml : 20240514 20240514073205 ACCESSION NUMBER: 0001428336-24-000022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 24941469 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20240509.htm 8-K hqy-20240509
0001428336false00014283362024-05-092024-05-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 9, 2024
HEALTHEQUITY, INC.

Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Introductory Note
This Current Report on Form 8-K is being filed in connection with the completion of the transactions contemplated by that certain Custodial Transfer and Asset Purchase Agreement (the “Purchase Agreement”), dated as of September 18, 2023, by and between HealthEquity, Inc., a Delaware corporation (“HealthEquity”), and Conduent Business Services, LLC, a Delaware limited liability company (“Conduent”).
Item 2.01    Completion of Acquisition or Disposition of Assets
On May 9, 2024, HealthEquity and Conduent completed the transactions contemplated by the Purchase Agreement. Pursuant to the Purchase Agreement, approximately 616,000 health savings accounts and other accounts and $2.7 billion of HSA assets were transferred from Conduent to HealthEquity in three separate tranches for an aggregate purchase price of $425.0 million. HealthEquity paid the aggregate purchase price using $225.0 million of borrowings under its revolving credit facility, with the remainder paid using cash on hand.
The foregoing description does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is filed herewith as Exhibit 2.1 and is incorporated by reference herein.
Item 7.01    Regulation FD Disclosure
On May 14, 2024, HealthEquity issued a press release announcing the completion of the closing, a copy of which is attached hereto as Exhibit 99.1.
The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits
(d) Exhibits
* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. HealthEquity hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: May 14, 2024By:/s/ James Lucania
Name:James Lucania
Title:Executive Vice President and Chief Financial Officer



 EX-99.1 2 a2024_5x13xfinalbenefitwal.htm EX-99.1 Document

image_0.jpg
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
Welcomes clients and members to its best-in-class platform.
DRAPER, UT — May 14, 2024 — HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio.
HealthEquity Chief Executive Officer, Jon Kessler said, "We are thrilled to welcome BenefitWallet clients and members as partners on our mission to save and improve lives by empowering healthcare consumers. We are committed to leading the health savings space by delivering remarkable service, deepening partnerships, and driving outcomes that matter to them."
HealthEquity welcomed more than 616,000 HSA members with approximately $2.7 billion in HSA Assets, of which approximately 34% are HSA investments. The newly onboarded members now have a wider range of HSA solutions, services, and options, including advanced investment and management tools and renowned Purple member and client support.
“With the addition of the BenefitWallet members, we now serve more than nine million HSA members and more than 16 million total accounts. Our members benefit from the investments we’ve made in the cloud, data analytics, automation, and the connectivity we deliver to our clients and partners across the health benefits ecosystem,” said HealthEquity Executive Vice President and CFO, James Lucania. “Our new BenefitWallet members are healthy savers, carrying above market balances with more than 85% of their HSA cash in Enhanced Rates. Combined, this represents a meaningful opportunity to provide continued value to these members and deliver a downpayment on our goal to double fiscal 2024 non-GAAP net income per share by the end of fiscal 2027.”
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 16 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to our mission to save and improve lives by empowering healthcare consumers. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our “Purple service” and approach at www.healthequity.com.
Investor Relations Contact:
Richard Putnam, HealthEquity, (801) 231-0697, rputnam@healthequity.com
Media Contact:
Amy Cerny, HealthEquity, 801-508-3237, acerny@healthequity.com


 EX-101.SCH 3 hqy-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hqy-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 hqy-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 09, 2024
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20240509.htm hqy-20240509.xsd hqy-20240509_lab.xml hqy-20240509_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hqy-20240509.htm": { "nsprefix": "hqy", "nsuri": "http://healthequity.com/20240509", "dts": { "inline": { "local": [ "hqy-20240509.htm" ] }, "schema": { "local": [ "hqy-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hqy-20240509_lab.xml" ] }, "presentationLink": { "local": [ "hqy-20240509_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://healthequity.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240509.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hqy-20240509.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://healthequity.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001428336-24-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-24-000022-xbrl.zip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end XML 18 hqy-20240509_htm.xml IDEA: XBRL DOCUMENT 0001428336 2024-05-09 2024-05-09 0001428336 false 8-K 2024-05-09 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false